MedTrace Logo

Safety and Tolerability Study for Age-Related Macular Degeneration

NCT01485588 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2020-11-06

Study results available
· View outcomes & findings →

Summary

Phase 1: The purpose of this study is to evaluate the safety and tolerability of single ascending doses of hI-con1™ for subjects with Age-Related Macular Degeneration.

Phase 2: The purpose of this study is to evaluate the safety of 3 injections of hI-con1™ at 2 different dose levels.

Conditions

  • Neovascular Age-Related Macular Degeneration

Interventions

DRUG

hI-con1™ 60µl

Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only

DRUG

hI-con1™ 150µl

Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only

DRUG

hI-con1™ 300µl

Phase 1: 60µl, 150µl, or 300µl per injection (in the eye) on Day 1 only

Sponsors & Collaborators

  • Iconic Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01485588 on ClinicalTrials.gov